Drug Profile
LM11A 31 BHS
Alternative Names: LM11A-31; LM11A-31-BHSLatest Information Update: 04 Nov 2022
Price :
$50
*
At a glance
- Originator University of California at San Francisco; University of North Carolina at Chapel Hill
- Developer PharmatrophiX
- Class Antidementias; Neuroprotectants; Small molecules
- Mechanism of Action Nerve growth factor receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Alzheimer's disease
Most Recent Events
- 28 Sep 2022 Phase-II development is ongoing in Austria, Czech Republic, Germany, Spain and Sweden (PO) (Pharmatrophix website, September 2022)
- 03 Aug 2022 Pharmacodynamics data from a phase II trial in Alzheimer's disease presented at the Alzheimer's Association International Conference (AAIC-2022)
- 08 Jun 2020 PharmatrophiX completes a phase II trial in Alzheimer's disease (In adults, In the elderly) in Austria, Czech Republic, Germany, Spain and Sweden (PO) (NCT03069014)